TL;DR
- 1.The '8 weeks on, 4 weeks off' rule has no clinical trial behind it. It is practitioner convention extrapolated from receptor biology theory.
- 2.A 30-day continuous GHRP-2 study found the GH axis still elevated 1.8x above baseline at day 30. Partial blunting, not a full shutdown.
- 3.For GLP-1 peptides like semaglutide, cycling is exactly the wrong approach. Stopping causes fat-preferential weight regain that continuous use prevents.
- 4.BPC-157 clears in under 30 minutes. The receptor occupancy argument for cycling does not apply to short-acting tissue-repair peptides.
- 5.Your GHSR and CYP3A4 variants affect how fast your GH axis resets. Your off-period length may need to differ from the population default.
The rule says cycle your peptides 8 weeks on, 4 weeks off, or your receptors burn out. For GH secretagogues, that advice has reasonable science behind it. For the GLP-1 class, including semaglutide and tirzepatide, it is the exact opposite of what the data supports. A 2022 extension of the STEP 1 trial published in Obesity (PMC9542252) followed patients who stopped semaglutide 2.4 mg after the main trial. Within 12 months, they had regained approximately two-thirds of their starting weight. The regained mass came back predominantly as fat, not lean tissue. Taking a break from a GLP-1 peptide is not a receptor reset. It is a weight set-point reset, and that is a fundamentally different problem.
The peptide cycling conversation fails most people because it applies one framework to mechanisms that require three completely different approaches. There are peptides that genuinely benefit from structured breaks, peptides where your goal rather than your receptor determines when to stop, and peptides where continuous use is the only strategy that works. Knowing which category you are dealing with changes everything about how you structure your protocol.
GH axis activation after 30 days of continuous GHRP-2. A 2004 study by Veldhuis et al. in the Journal of Clinical Endocrinology and Metabolism (PMID 15126555) found growth hormone secretion still elevated 1.8-fold above baseline at the end of a 30-day uninterrupted infusion. The axis blunts and stabilizes. It does not crash.
The most commonly cited reason to cycle GH secretagogues is receptor downregulation: continuous activation of the ghrelin receptor (GHSR-1a) or the GHRH receptor causes the receptor to internalize, reducing surface availability and blunting response over time. This is real and confirmed in humans. The part the cycling advice usually overstates is the severity. The axis does not shut off. It dials back to a new steady state and holds there. In the Veldhuis protocol, IGF-1 and its binding proteins remained stably elevated throughout the entire 30-day infusion period, even as GH pulse amplitude moderated from 3-fold to 1.8-fold above baseline.
A follow-up finding from the same research period makes the practical implication clear: hexarelin is the one GHRP that desensitizes rapidly enough to be genuinely problematic for extended protocols. Ipamorelin and GHRP-2 show partial, plateauing blunting that does not progress to clinical failure. The cycling urgency commonly applied to all GH secretagogues was built around hexarelin pharmacology and then extended by convention to compounds with considerably more forgiving receptor behavior.
Think of your ghrelin receptor like a stage crew operating a spotlight. Every GHRP injection tells the crew to hit the light. After weeks of constant demands, some crew members take informal breaks and the light output drops to about 60% of opening night. The cycling advice implies the crew eventually walks out entirely. The Veldhuis data shows they stay on the job at reduced capacity, still delivering meaningful output. That is a different problem with a different solution, and it does not require the same dramatic off-period that complete crew turnover would.
Which Peptides Actually Need a Structured Break?
The answer depends on whether your peptide works through a receptor pathway that internalizes under continuous activation, and whether its mechanism is pulsatile or tonic by nature. The three categories are distinct enough that applying one cycling framework to all of them produces at least one wrong call for most people.
Ipamorelin, GHRP-2, GHRP-6, and CJC-1295 all work through receptors that partially desensitize under continuous use. Hexarelin is the class outlier: rapid desensitization makes it impractical for extended protocols. Ipamorelin and GHRP-2 show blunting that plateaus rather than progresses to shutdown. The 5-days-on/2-days-off weekly pattern and the 12-to-16 week active cycle with a 4-to-8 week break exist for a legitimate biological reason: partial receptor recovery during the off period allows the axis to return closer to its pre-cycle response state. This class benefits from structured cycling. The Veldhuis data just tells us the urgency is lower than most guides imply.
BPC-157 clears from the bloodstream in under 30 minutes following intravenous administration in animal models, based on 2022 ADME pharmacokinetic data published in Frontiers in Pharmacology (PMC9794587). This elimination kinetic makes receptor occupancy concerns largely irrelevant: the receptor is never under sustained occupation long enough to trigger the internalization pattern seen with continuous GHRPs. No published data demonstrates tolerance development to BPC-157 under standard subcutaneous dosing. Run it until you have achieved your healing goal, then stop. For TB-500, the same outcome-driven logic applies, with the additional consideration that tissue depot accumulation changes the dosing math. The TB-500 and BPC-157 half-life guide explains how each peptide's tissue accumulation pattern determines your actual schedule.
Semaglutide and its analogs do not follow the receptor cycling logic that applies to GHRPs. Their mechanism involves chronic remodeling of appetite signaling, gut hormone patterns, and adipose tissue set-point regulation. It is not a pulsatile receptor trigger that desensitizes in the same way. Stopping introduces a set-point rebound that is not fully reversed on restart. The STEP 1 extension data showed that after discontinuation, patients regained approximately two-thirds of lost weight within 12 months, with the regained mass skewed heavily toward fat rather than lean tissue. Your GLP-1 receptor is not what resets when you stop semaglutide. Your adipose set-point is. These are fundamentally different biology, and the cycling logic appropriate for GHRPs does not transfer here.
| Peptide or Class | Receptor Desensitization? | Recommended Pattern | Primary Cycling Driver |
|---|---|---|---|
| Ipamorelin | Partial, plateaus around day 14 | 5-on/2-off weekly; 12-16 weeks on, 4-8 weeks off | Receptor recovery |
| CJC-1295 | Low to moderate | 12-16 weeks on, 4-6 weeks off | Receptor and HPTA modulation |
| GHRP-2 | Partial, similar to ipamorelin | 5-on/2-off; 8-12 weeks on, 4 weeks off | Receptor recovery |
| Hexarelin | Rapid, clinically significant | Short burst use only; not suitable for extended runs | Receptor recovery (urgent) |
| BPC-157 | Not established in literature | Goal-based: run until the healing objective is met | Tissue outcome |
| TB-500 | Not established in literature | Loading phase 4-6 weeks, then maintenance or stop | Tissue depot saturation |
| Semaglutide | Not the limiting factor | Continuous: stopping resets weight set-point, not receptor | Set-point management |
| Selank | Low: short half-life, acute mode | As-needed or short course; not receptor-limited | Neurochemical baseline |
Continuous GLP-1 receptor stimulation produced rapid tachyphylaxis of gastric emptying deceleration, while the insulinotropic response was largely preserved. Intermittent stimulation maintained the gastric emptying response significantly better than continuous infusion. The mechanisms of desensitization differ by downstream effect, not by receptor identity alone.
Nauck et al., Diabetes, 2011 (PMID 22611063)
The Nauck finding has a practical implication beyond GLP-1 protocols: tachyphylaxis is effect-specific, not peptide-specific. The same receptor can desensitize for one downstream effect while holding stable for another. For GH secretagogues, GH pulse amplitude blunts while IGF-1 remains elevated. This means the "is it still working?" question depends entirely on what you are measuring. If you are tracking GH pulse quality (sleep depth, morning energy, training pump), you may perceive diminishing returns after 2 to 4 weeks. If you are tracking body composition or IGF-1 labs, the Veldhuis data suggests meaningful axis activation continues at day 30. For a detailed comparison of how ipamorelin and CJC-1295 produce different signal types from the same GH axis, see the ipamorelin vs. CJC-1295 comparison.
Why the "8 Weeks On, 4 Weeks Off" Rule Exists (and What It Cannot Tell You)
The standard cycling protocol is practitioner convention, not a clinical trial result. No randomized controlled study has compared an 8-on/4-off cycling regimen against continuous GHRP use in humans and measured which produces better long-term outcomes, lower side-effect burden, or preserved receptor sensitivity at 6 or 12 months. The protocol is an extrapolation from three sources: known GPCR internalization kinetics from in vitro and animal work, the Veldhuis-type continuous infusion data showing partial human blunting, and cycling convention borrowed from anabolic steroid protocols that may or may not translate to peptide receptor pharmacology.
That does not mean the protocol is wrong. Partial receptor recovery during the off period is biologically plausible and consistent with known GPCR trafficking dynamics. The 5-days-on/2-days-off weekly pattern specifically mirrors the body's own pulsatile GH axis, which produces its largest natural pulses during deep sleep and naturally quiets during peak cortisol hours. Injecting before sleep on training recovery days and pausing on high-intensity training days aligns the exogenous signal more closely with endogenous rhythm. The FDA's Pharmacy Compounding Advisory Committee noted in its December 2024 briefing document for CJC-1295 that immunogenicity and continuous stimulation of the GHRH receptor represent unresolved safety considerations, which provides an independent regulatory rationale for favoring pulsatile over continuous approaches for that specific compound.
What the protocol cannot tell you is whether your particular off period is long enough for your receptor to recover, or whether it is longer than necessary and costing you accumulated gains. That requires a measurement, not a calendar entry.
Weight regained within 12 months of stopping semaglutide 2.4 mg, from the STEP 1 trial extension published in Obesity (PMC9542252). The regained mass was predominantly fat, not lean tissue. The GLP-1 receptor had not burned out during the original trial period. It had been continuously managing a set-point signal. Removing the signal removed the managed state.
How to Know When Your Receptors Have Actually Reset
Every cycling guide says take 4 weeks off. None of them tell you what signal confirms you are ready to restart. There are two practical approaches, and one is considerably more informative than the other.
The lab-based approach uses IGF-1 as a proxy for GH axis baseline. If your IGF-1 rose meaningfully during a GH secretagogue cycle, taking 4 to 8 weeks off should allow it to return close to its pre-cycle level. That return is the pharmacological signal that the axis has reset to a state where a new cycle can produce meaningful upward movement again. Testing IGF-1 at the start of your off period and again before you restart gives you actual data. Some practitioners add a week or two beyond the calendar target if IGF-1 has not returned to within 15% of baseline. The cost is a blood panel. The benefit is knowing rather than guessing.
The subjective signal is simpler and less precise: when you restart after the break, do the first-week effects feel qualitatively stronger than the plateau at the end of your previous cycle? A genuine receptor reset produces a noticeably different first-week response: deeper sleep on ipamorelin, faster morning recovery, stronger perceived pulse. If restarting feels identical to the plateau at the end of your last run, the receptor has not recovered meaningfully and extending the off period is the right call before escalating dose.
Why Your Genetics Changes the Reset Timeline
Receptor recovery rate is not uniform across people. GHSR loss-of-function variants, present in roughly 3 to 5% of people based on a 2025 characterization in the Journal of Clinical Endocrinology and Metabolism (PMC12012706), mean lower baseline receptor availability before a cycle starts, which affects both GH pulse magnitude and the timeline for recovery after cycling off. If your ghrelin receptor is operating at reduced capacity from the outset, a standard 4-week off period may underestimate what you need for a meaningful reset. Separately, slow CYP3A4 metabolizers clear long-acting analogs like CJC-1295 more slowly than standard pharmacokinetics assume, so plasma concentrations accumulate higher and receptor occupancy extends further into the nominal off period than the calendar suggests. The DNA-first peptide decision framework explains how metabolic gene variants translate into protocol adjustments, including how to personalize the off-period length relative to the population default.
The One Mistake That Makes Cycling Worse, Not Better
Raising your dose when a GH secretagogue appears to stop working mid-cycle is the most common mistake in GHRP protocols, and it actively worsens the problem it is intended to fix. Increasing dose under partial receptor downregulation accelerates internalization, compressing your remaining effective window rather than restoring it. The dose escalation impulse is understandable: you felt it working at week 2, you want that back at week 8, and more seems like the logical lever. What you are feeling at week 8 is the plateau state, not failure. The axis is still producing meaningful IGF-1 elevation, just not the dramatic first-week GH pulse quality. Forcing escalation through that plateau pushes the receptor further into the internalization pattern, making subsequent cycles progressively less responsive even after adequate off periods. The correct response to a mid-cycle plateau is a short 5-to-7 day mini-break, a dose reduction to the lowest effective level, or an acceptance that the plateau is still delivering results even if it does not feel that way subjectively.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Do I need to cycle BPC-157?
BPC-157 clears from the bloodstream in under 30 minutes, which makes the receptor occupancy argument for cycling largely inapplicable. No published data demonstrates tolerance development to BPC-157 under standard subcutaneous dosing. Run it until you have achieved your healing goal, then stop. Restart if the underlying issue recurs, not on a fixed calendar schedule.
How long should I cycle off ipamorelin?
The clinical convention is 4 to 8 weeks off for every 12 to 16 weeks on. No trial has confirmed this specific ratio as optimal. The practical signal for restart readiness is an IGF-1 return close to your pre-cycle baseline, which a simple blood panel can confirm. Calendar-based timing is a rough proxy; lab confirmation is more accurate.
What happens if you take peptides without cycling?
For GH secretagogues, continuous use produces partial receptor blunting rather than a full shutdown. The Veldhuis 2004 study found GHRP-2 still elevated GH 1.8x above baseline after 30 days of uninterrupted use, with IGF-1 stably elevated throughout. For BPC-157, no tolerance pattern has been established. For GLP-1 peptides like semaglutide, continuous use is the correct protocol: stopping causes fat-preferential weight regain.
Why did my peptides stop working?
The most common causes are partial receptor downregulation for GH secretagogues, dose escalation mid-cycle that accelerated desensitization, a natural plateau where the axis reached a new steady state, or reaching the natural endpoint of what the peptide can achieve for your goal. A 4-to-8 week off period followed by IGF-1 testing typically distinguishes receptor fatigue from goal completion.
Can you take semaglutide continuously without a break?
Yes, and continuous use is the recommended approach for GLP-1 peptides. The STEP 1 trial extension found patients who stopped semaglutide regained approximately two-thirds of their lost weight within 12 months, with the regained mass predominantly fat rather than lean tissue. GLP-1 peptides manage a continuous appetite and set-point signal: removing the signal removes the managed state, not the underlying condition.
Does ipamorelin lose effectiveness over time?
Partially. Human data on continuous GHRP administration shows GH pulse amplitude moderates after 2 to 4 weeks of daily use, then stabilizes above baseline rather than declining to zero. IGF-1 tends to remain elevated throughout even as the subjective GH pulse feel diminishes. The 5-days-on/2-days-off weekly pattern helps maintain closer to the day-1 pulse quality over longer protocols.
What is a good first peptide cycling protocol?
For ipamorelin or an ipamorelin-CJC-1295 combination, a solid starting point is 12 weeks on followed by 4 weeks off. During the active phase, inject on 5 consecutive nights and skip 2 days each week, timing doses before sleep when endogenous GH secretion is naturally highest. Do not escalate dose if you plateau mid-cycle: dose escalation under partial receptor downregulation accelerates the problem rather than reversing it.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.